title: Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.
abstract: Paliperidone palmitate (PP) is a recently introduced long-acting atypical, or second-generation, antipsychotic. Published data on PP are currently limited to controlled trials and case reports. In this observational study, we followed up 200 consecutive patients prescribed PP in normal practice. After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year, 3 years before initiation (P=0.0001). The mean number of bed days fell from 38.78 to 23.09/patient/year over the corresponding period (P=0.0001). The median number of bed days 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0. Outcomes were numerically but not statistically better in those continuing PP than in those who ceased PP within a year of initiation. PP was effective and well-tolerated and, given its positive effect on hospital bed days, broadly cost-effective.
authors.affiliation: aPharmacy Department, Maudsley Hospital bInstitute of Pharmaceutical Science, King's College London, London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Taylor
authors.forename: Olubanke
authors.initials: O
authors.lastname: Olofinjana
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D015331:Cohort Studies; D003692:Delayed-Action Preparations / Q000009:adverse effects; D016903:Drug Monitoring; D057286:Electronic Health Records; D005260:Female; D005500:Follow-Up Studies; D006786:Hospitals, Urban; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007902:Length of Stay; D008131:London; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate; D010168:Palmitates / Q000009:adverse effects / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy*; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D010168:Palmitates; D000068882:Paliperidone Palmitate